This relaxant response was NO- and endothelium-dependent, as shown by the full inhibitory effect of either endothelium removal or incubation with N -Nitro-L-arginine methyl ester hydrochloride (L-NAME) (Fig.?4). Open in a separate window Fig. was quantified in reverse transcriptaseCquantitative polymerase chain reactions. Results Ach-induced relaxation was much less intense in smokers than in never-smokers (respectively 24??6% and 50??7% with 10?4M Ach; dimethylbenzenamine, Calbiochem, Darmstadt, Germany , ref. 373401)) and an SHH pathway agonist (SAG: 3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-5[[3-(4-pyridinyl)-phenyl]methyl]-1-benzothiophene-2-carboxamide, sc-212905, Santa Cruz Biotechnology, Lexington, KY, USA). Cyclopamine is a plant-derived alkaloid that binds to the SHH pathway transducer SMO and stabilizes it in an inactive form – thereby blocking SHH signalling [27]. GANT61 inhibits the SHH pathway by specifically blocking the binding of GLI1 and GLI2 to their DNA targets [28, MYO5A 29]. GANT61 (5?M) and cyclopamine (0.1?M) were dissolved in dimethyl sulfoxide (DMSO. The SHH pathway agonist SAG binds to SMO [27] . SAG was dissolved in water. Certain rings were incubated with recombinant human VEGF 165 (R&D Systems Europe, Abingdon, UK; 1?ng/ml) for 45?min after incubation with PE. The concentrations Lersivirine (UK-453061) of these drugs used in the present pharmacological experiments had previously been determined to be those producing 50% of the maximal effect (i.e. the EC50) in pulmonary artery rings Lersivirine (UK-453061) (data not shown). All other drugs were purchased from Sigma Aldrich (St Quentin Fallavier, France). All experiments were performed in duplicate. The inter-ring variability was always below 10%. RNA isolation and reverse transcriptase C quantitative polymerase chain reaction (RT-qPCR) analysis Pulmonary artery rings were placed at ?80?C in TRIzol reagent (Invitrogen, Carlsbad, CA) for subsequent mRNA extraction. The RT-qPCR experiments were performed as described in our previous work [30]. Pulmonary artery rings were crushed and homogenized in TRIzol reagent, using a Tissue-Lyser LT ball mill (Qiagen, Courtaboeuf, France). Total RNA was extracted from arterial homogenates using TRIzol. The amount of RNA extracted was estimated by spectrophotometry at 260?nm (Biowave DNA; Biochrom, Cambridge, UK) and the quality of the preparation was assessed in a microfluidic electrophoresis system (RNA Standard Sensitivity kits for Experion, BioRad, Marnes-la-Coquette, France). After treatment with DNase I (Life Technologies, Saint Aubin, France), 1?g of total RNA was reverse-transcribed (SuperScript III First-Strand SuperMix kit, Life Technologies). The resulting cDNA was then used for RT-qPCR experiments with TaqMan chemistry (Life Technologies). After initial denaturation at 95?C for 10?min, 20?ng of cDNA were amplified (using Gene Expression Master Mix, Life Technologies) in 40 annealing/extension cycles (95?C for 15?s and 60?C for 1?min) in a StepOnePlus thermocycler (Life Lersivirine (UK-453061) Technologies). The samples fluorescence was measured after each cycle, and the threshold cycle (Ct) of the real-time PCR was defined as the point at which a fluorescence signal corresponding to the amplification of a PCR product was detectable. The reaction volume was 10?l. The following genes were tested: chronic obstructive pulmonary disease, defined by post bronchodilator FEV1/FVC?p?=?0.028) (Fig.?1). Open in a separate window Fig. 1 Pulmonary endothelial function, represented as cumulative Ach dose response curves in pulmonary artery rings from smokers (n?=?34) and never-smokers (n?=?8). Rings from smokers displayed impaired relaxation in response to Ach, when compared with rings from never-smokers (p?=?0.028) SHH modulation alters pulmonary vasodilationWe tested the effect of SHH inhibition in pulmonary artery rings from smokers. The downstream SHH inhibitor GANT61 strongly altered vasodilation (2??7% vs. 23??6% at Ach 10?4M in the presence and absence of GANT61, respectively; n?=?27, p?n?=?27; Fig.?2b) nor SHH activation by SAG (n?=?27; Fig.?2c) had a significant effect on the relaxation response. Open in a separate window Fig. 2 Effect of SHH modulation on pulmonary artery ring relaxation. Treatment with the downstream SHH inhibitor GANT61 altered vasodilation (n?=?27; p?n?=?27) had no effect (b). SHH activation with SAG (n?=?27) had no effect (c) SHH genes are expressed in pulmonary artery ringsmRNAs from all known genes involved in the response to SHH were expressed in pulmonary artery rings from smokers (n?=?11; Fig.?3). Open in a separate window Fig. 3 SHH gene expression in pulmonary artery rings. All genes of the SHH pathway are expressed in pulmonary arterial rings from smokers (n?=?11) VEGF restores vasodilation in pulmonary artery ringsTo further assess the potential vascular effect of the SHH pathway, we investigated one of its main targets: VEGF. To this.